Protein Kinase C (19-31) CAS NO.121545-65-1

<p>Protein Kinase C (19-31) is a synthetic 13-amino acid peptide inhibitor, also known as PKC(19-31) or the PKC pseudosubstrate inhibitor. With the sequence <strong>RFARKGALRQKNV</strong>, it corresponds to the pseudosubstrate regulatory domain of conventional Protein Kinase C (cPKC) isoforms (α, β, γ). This peptide mimics the substrate recognition sequence of PKC but contains an alanine (A) residue instead of a pho…

SupplierGlobal Technology Co., Ltd.www.hqtechtirz.com

View on supplier website More from this supplier

Source categories

Peptides

About this product

Product information from the supplier.

TECHNICAL SPECIFICATIONS

Item	Specification
Product Name	Protein Kinase C (19-31)
CAS NO.	121545-65-1
Appearance	White to off-white lyophilized powder
Molecular Formula	C67H118N26O16
Molecular Weight	1543.84g/mol
Purity (RP-HPLC)	≥ 95.0%
Solubility	Soluble in water, 0.1% TFA, or DMSO (up to 20 mg/mL)
Endotoxin	≤1.0 EU/mg
Biological Activity	Acts as a specific substrate for Protein Kinase C; can be used to measure PKC activity in kinase assays and to validate antibody specificity
Storage Conditions	Store at -20°C; stable for 24 months when desiccated. Avoid repeated freeze-thaw cycles.
Stock Location	Stock in USA
MOQ	1g

1.MECHANISM OF ACTION

PKC(19-31) functions as a competitive, substrate-specific inhibitor of conventional Protein Kinase C (cPKC) isoforms (α, βI, βII, γ). Its mechanism is based on molecular mimicry. Inactive cPKC is autoinhibited by its own pseudosubstrate domain, which occupies the catalytic cleft. Upon activation by diacylglycerol (DAG) and calcium, this inhibitory interaction is released.

2.PRODUCT INDICATIONS

PKC(19-31) functions as a competitive, substrate-specific inhibitor of conventional Protein Kinase C (cPKC) isoforms (α, βI, βII, γ). Its mechanism is based on molecular mimicry. Inactive cPKC is autoinhibited by its own pseudosubstrate domain, which occupies the catalytic cleft. Upon activation by diacylglycerol (DAG) and calcium, this inhibitory interaction is released.

3.CLINICAL EFFICACY OF PRODUCT

Research Tool Efficacy: It is highly effective and widely cited for its ability to potently and selectively inhibit cPKC activity in a wide range of cellular and biochemical experiments, providing clear mechanistic insights.
Therapeutic Target Validation: Research using this and similar inhibitors has been instrumental in establishing the pathological roles of specific PKC isoforms in diseases such as cancer, diabetic complications, cardiovascular diseases, and central nervous system disorders.
Drug Development Context: The pseudosubstrate region of PKC served as the conceptual blueprint for developing ATP-competitive small-molecule PKC inhibitors. While early pan-PKC inhibitors had toxicity issues, isoform-selective inhibitors (e.g., ruboxistaurin for diabetic retinopathy) have been developed and tested in clinical trials based on the foundational knowledge gained using tools like PKC(19-31).
Clinical Status: No peptide-based PKC inhibitor like PKC(19-31) is used clinically due to stability and delivery challenges. However, the pathway it helps to elucidate is targeted by several investigational drugs. Its value is entirely in preclinical target validation and mechanism elucidation.

4.DELIVERY & SHIPPING

We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods
Main Method: International Air Freight

We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.